KOD Shorts Retreat as Baker Bros. Tightens Grip

Kodiak Sciences is a clinical-stage biotech developing treatments for blinding eye diseases, and after a 182% rally over the past month it now finds itself in an unusual position: short sellers are leaving, an activist is consolidating, and options traders have turned notably bullish, all ahead of a November 12 earnings print.

The short side tells a clear retreat story. Short interest has dropped 25% over the past month to 15% of the free float, down from roughly 22% at the start of October. The weekly decline of 9.8% continues a trend that began in late September, when shares were still in the $30s. Despite that elevated float percentage, borrow conditions are anything but strained. Availability has actually loosened dramatically, running at 1,154% of short interest, meaning there are more than eleven shares available to lend for every one already borrowed. That compares with a 52-week low availability reading of 402%. Cost to borrow is 0.46%, barely above the general collateral rate. This is not a squeeze setup. Shorts are covering into strength, not being forced out.

Options positioning reinforces the bullish tilt. The put/call ratio has collapsed to 0.51, nearly 1.3 standard deviations below its 20-day average of 1.02. For most of September and early October, the PCR ran above 1.2 to 1.4, reflecting heavy demand for downside protection while the stock was still recovering. That protective layer has unwound sharply in the past two weeks as the stock pushed above $90, and call activity now clearly dominates. The 52-week low on the PCR is 0.19, so there is still room to move further, but the direction of travel is unambiguously more bullish than it has been all year.

The ownership picture carries a headline of its own. Baker Bros. Advisors, the healthcare-focused investment firm, holds an activist Schedule 13D position and disclosed a stake of 35% of the class in a September 30 filing, up from 32.8% previously. That is a dominant, concentrated position and the 13D designation signals active rather than passive intent. D. Victor Perlroth, listed separately as a 13G holder at 9.9%, adds further insider-adjacent concentration. T. Rowe Price reported adding 1.85 million shares in Q3 to reach 7.5% of the company. BlackRock added 200,000 shares to reach 6.6%. The register is becoming more concentrated, not less, as the stock has risen. Positions are as last disclosed around the 5% threshold; holders can drop below that level without a further filing.

The recent insider activity warrants a note, though the read is mixed. The CFO, John Borgeson, exercised options and sold just over $2.5 million of stock on October 21, but all transactions were conducted under a pre-arranged 10b5-1 plan. Planned sales carry far less signal than discretionary ones. The broader 90-day net insider figure is a positive $67 million, reflecting the large option-exercise-and-hold activity that has accompanied the stock's rise.

Analyst targets have moved sharply higher following the stock's repricing. HC Wainwright raised its target to $126 in mid-October and UBS moved to $120 at the end of September, both maintaining buy-equivalent ratings. LifeSci Capital went furthest at $145. Goldman Sachs reinstated coverage with a Neutral rating and a $36 target in late September. That $36 target now looks materially out of step with the current $91 price and likely reflects timing rather than a current view. The consensus mean target of $122 carries a modest 33% premium to Tuesday's close, modest given that this stock moved 182% in a month. The analyst recommendation factor score ranks in the 93rd percentile of the ORTEX universe, reflecting how bullish the covering analysts are relative to the broader market.

ORTEX puts the probability of KOD joining the CRSP US Small index at the December 2026 Quarterly Review at 28%. The stock needs to close above $92.76 to qualify, roughly 1.6% above Tuesday's close of $91.32. If the index rule flips in KOD's favour, ORTEX estimates index trackers would need to buy approximately $54 million of stock, equivalent to about 0.3 days of normal trading volume. The rank date is December 4, with announcement expected December 7 and the trade settling December 22.

The November 12 earnings date is the clearest near-term focus point for all of these positioning shifts. The prior four results events produced one-day moves of +2.5%, -4.7%, -8.2%, and -6.5%. Three of those four prints saw the stock lower on the day, and all four saw further weakness over the subsequent five days in at least three instances. Whether the heavily rebalanced ownership base and sharply reduced short interest changes that pattern is the question the data cannot answer.